Nexus NeuroTech

CEO Alex Tarrand and CIO Sourav Sengupta lead the investment committee. Both co-founders are involved in sourcing, diligence, and portfolio management for all transactions. The firm has not publicly disclosed additional investment partners or an expanded IC structure, consistent with an early-stage specialist platform operating with a lean senior team.

Nexus NeuroTech operates as a specialized asset manager, not a family office. The firm is structured as a Delaware-registered limited liability company and raises capital through fund structures rather than managing a single family's wealth. It does not offer multi-family office services.

The firm targets early-stage investments from seed through Series B. Check sizes are estimated at $1 million to $5 million per initial commitment, with capacity to follow on in subsequent rounds. Nexus NeuroTech typically leads or co-leads rounds, consistent with a concentrated-portfolio approach rather than passive index-style exposure.

Nexus NeuroTech does not invest in general digital health, traditional biopharma, medical devices outside neural interfaces, or pure software-as-a-service businesses. The firm's mandate excludes non-neurological therapeutic areas, wellness apps without regulatory clearance pathways, and hardware companies without brain-interface or neuromodulation core technology.

The firm sources primarily through academic neuroscience hubs, neural-engineering conferences, and relationships with university technology-transfer offices. Co-founders Tarrand and Sengupta have positioned the firm as a domain-specialist partner to neurotech founders, which generates proprietary flow distinct from auction processes run by generalist VCs.